Publications by authors named "Sandy Griffith"

Claim this Profile
T
The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans.
Rosie Mngqibisa, Yashna Singh, Catherine Orrell, Johan Lombaard, Sandy Griffith

South Afr J HIV Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
Maggie Czarnogorski, Paul Benn, Cindy McCoig, Toyin Nwafor, Sandy Griffith

J Acquir Immune Defic Syndr· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the Potency of Cabotegravir or Rilpivirine.
Jerry L Jeffrey, Marty St Clair, Ping Wang, Chunfu Wang, Zhufang Li, Sandy Griffith

Antimicrob Agents Chemother· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Chloe Orkin, Enrique Bernal Morell, Darrell H S Tan, Harold Katner, Hans-Jürgen Stellbrink, Sandy Griffith

Lancet HIV· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Chloe Orkin, Shinichi Oka, Patrick Philibert, Cynthia Brinson, Ayesha Bassa, Sandy Griffith

Lancet HIV· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.
Andrea Mantsios, Miranda Murray, Tahilin S Karver, Wendy Davis, David Margolis, Sandy Griffith

AIDS Behav· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
Miranda Murray, Antonio Antela, Anthony Mills, Jenny Huang, Hans Jäger, Sandy Griffith

AIDS Behav· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Giuliano Rizzardini, Edgar T Overton, Chloe Orkin, Susan Swindells, Keikawus Arasteh, Sandy Griffith

J Acquir Immune Defic Syndr· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
Miranda Murray, Federico Pulido, Anthony Mills, Moti Ramgopal, Roger LeBlanc, Sandy Griffith

HIV Res Clin Pract· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Chloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, Vadim Pokrovsky, Edgar T Overton, Sandy Griffith

N Engl J Med· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, Joseph J Eron, Yazdan Yazdanpanah, Sandy K Griffith

Lancet· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
David A Margolis, Cynthia C Brinson, Graham H R Smith, Jerome de Vente, Debbie P Hagins, Sandy K Griffith

Lancet Infect Dis· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.
Ann K Miller, Emma Harrell, Li Ye, Sharon Baptiste-Brown, Jőrg-Peter Kleim, Sandy Griffith

Br J Clin Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Pedro Cahn, Anton L Pozniak, Horacio Mingrone, Andrey Shuldyakov, Carlos Brites, Sandy Griffith

Lancet· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.
John A Bartlett, Judy Johnson, Gisela Herrera, Nestor Sosa, Alan Rodriguez, Sandy Griffith

J Acquir Immune Defic Syndr· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Jeffrey P Nadler, Joseph C Gathe, Richard B Pollard, Gary J Richmond, Qiming Liao, Sandy Griffith

BMC Infect Dis· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis